Form D · Pharmaceuticals
Retension Pharmaceuticals, Inc.
Mclean, VA · CIK 0002002988
Offering snapshot reported May 6, 2025 · SEC filing
- Reported sold
- $12.3M Offering amount: $20M
- Investors reported
- 98 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2025 | Initial | $12,288,567 | No comparison | 98 | SEC filing |
| May 15, 2024 | Amendment | $10,143,750 | $4,323,850vs Dec 5, 2023 | 132 | SEC filing |
| Dec 5, 2023 | Initial | $5,819,900 | No comparison | 82 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $701K (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-545343
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Collage Venture Partners, LLC | 316063 | |
| Stonehaven, LLC | 118913 |
Source: Form D, filed May 6, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Berendt | Director |
| Eric Keller | Director, Executive |
| Donald Olds | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Redux Therapeutics, Llc 902 Turkey Run Road
Mclean, VA, 22101
Phone: (703) 624-2024
Mclean, VA, 22101
Phone: (703) 624-2024